Corbus's lead drug
succeeds in mid-stage scleroderma study
Send a link to a friend
[November 14, 2016]
(Reuters) - Corbus Pharmaceuticals
Holdings Inc said its lead drug outperformed a placebo in a mid-stage
study involving patients with a form of systemic sclerosis, an incurable
autoimmune condition caused by abnormal growth of connective tissue.
The trial tested the drug, resunab, against a placebo in patients
with diffuse cutaneous systemic sclerosis, the less common form of
the condition that has a higher risk of death.
Patients on resunab scored 33 percent on an index that evaluates
changes in skin hardening and lung capacity, while those on the
placebo scored zero after 16 weeks, Corbus said on Monday.
A score of 20 percent or more is considered clinically meaningful.
Systemic sclerosis, also called scleroderma, comes from the Greek
words for "hard skin". The disease is characterized by vascular
damage and scarring or fibrosis of the skin, the gastrointestinal
tract, heart, lungs and other internal organs.
No existing drug can stop the progression of systemic sclerosis, but
there are medicines that can relieve certain symptoms and reduce
(Reporting by Natalie Grover in Beng
[© 2016 Thomson Reuters. All rights
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.